TRACON Pharmaceuticals Inc. Stock Analysis TCON

TRACON Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 17 full-time employees. The company went IPO on 2015-01-30. TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.